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Background: Scaling Up Rapid
Diagnostic Tests
Since 2007, the World Health Organi-
zation (WHO) has approved an unprece-
dented number of new diagnostic tests for
tuberculosis (TB) [1,2]. Most recently,
Xpert MTB/RIF (Cepheid, Inc.; Sunny-
vale, CA), an automated polymerase chain
reaction (PCR) test with high accuracy in
validation studies (72%–77% sensitivity for
smear-negative TB, 99% specificity) [3,4],
was endorsed by WHO [5] and reduced in
price [6]. To impact TB globally, Xpert
MTB/RIF and other diagnostics must be
scaled-up across numerous clinical set-
tings, after careful evaluation of expected
costs and benefits. Unfortunately, standard
cost-effectiveness analyses are ill-suited to
guide local decision-makers in directing
scale-up activities. We demonstrate the
limitations of standard economic analyses
as applied to scale-up of TB diagnostics
(specifically Xpert MTB/RIF), and rec-
ommend adaptations to future analyses
that will facilitate rational and effective
scale-up activities.
Economic Analysis of TB
Diagnostics: Current Practice
Decision analysis is the most widely-
used methodology for evaluating health
interventions’ cost-effectiveness [7]. Deci-
sion analyses have assessed many TB
diagnostics, including liquid culture [8],
line probe assays [9], and theoretical
point-of-care tests [10]. When applied to
diagnostic tests, decision analysis must
estimate the probability, economic cost,
and effectiveness for each of four possible
test results: true positive, true negative,
false positive, and false negative. These
quantities are calculated separately with
and without a new diagnostic test; the
incremental cost-effectiveness ratio (ICER)
describes the difference in cost, divided by
the difference in effectiveness, between the
two scenarios. The ICER, often reported
as the cost per disability-adjusted life year
(DALY) averted, may be compared
against a selected benchmark, such as
per-capita gross domestic product (GDP)
[11].
For example, a simple decision analysis
might evaluate a hypothetical cohort of
TB suspects undergoing diagnosis with
sputum smear microscopy versus Xpert
MTB/RIF (Figure 1). The number of true
positives, true negatives, false positives,
and false negatives (diagnostic outcomes)
are calculated by applying test sensitivity
and specificity to the cohort prevalence of
active TB. Estimates from the literature or
data from field evaluations inform the
mean cost and effectiveness (in DALYs) for
each of these four outcomes under the two
diagnostic strategies. For each outcome,
cost and effectiveness are multiplied by
probability to estimate the overall cost and
effectiveness of sputum smear versus Xpert
MTB/RIF. Additional assumptions and
calculations can expand the analysis to
include other diagnostic tests or more
faithfully represent the diagnostic process,
but the probability, cost, and effectiveness
of each outcome must be calculated to
generate cost-effectiveness ratios. In these
essential steps of decision analysis, three
key challenges arise when evaluating TB
diagnostics:
(1) The costs of false-positive diagnoses
are poorly defined and often under-
estimated.
(2) Diagnostic accuracy (i.e., sensitivity
and specificity) is an inadequate proxy
of outcomes important to patients and
public health.
(3) Diagnostic testing often competes for
resources with other TB-specific in-
terventions, making standardized
cost-effectiveness thresholds largely
irrelevant.
Challenge #1: Estimating the
Cost of False-Positive
Diagnoses
Whereas the costs of false-negative TB
diagnoses can be summarized by project-
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(including transmission), the costs of false-
positive diagnoses are difficult to estimate.
Published studies generally confine their
estimates to the costs of diagnostic testing,
inappropriate disease treatment, and man-
agement of medication side effects [12].
However, false-positive TB diagnoses may
cause morbidity and mortality from other
conditions for which treatment is delayed
on the basis of a rapidly false-positive TB
test. Furthermore, false-positive diagnosis
may lead to overuse of TB drugs, increas-
ing risks for acquired drug resistance.
These costs to patients and society are
not incorporated into most decision anal-
yses, which therefore tend to overestimate
the cost-effectiveness of TB diagnostics.
More importantly, the economic costs of
TB treatment are miniscule relative to the
costsofuntreatedTB.Infact,mostanalyses
underestimate the costs of untreated TB by
not accounting for the costs of transmission
from untreated cases. Because untreated
TB carries such high costs, standard
analyses favor any diagnostic test that
increases the number of TB cases treated,
even if it generates more false-positive
diagnoses than most physicians and pa-
tients would accept. For example, in
Rwanda, it has been argued that treating
29 false-positives for every additional case
of active TB would be cost-effective [13].
Similarly, a US$20 TB diagnostic test with
15% sensitivity and 50% specificity would
be recommended on standard cost-effec-
tiveness grounds [10]. However, it is
unlikely that patients or physicians would
accept a diagnosis that is wrong 29 times
out of 30, or a test performing more poorly
than a coin flip. Estimates of the true cost of
false-positive TB diagnosis must account
for these values and preferences.
The consequences of underestimating
costs from false-positive diagnoses are mag-
nified as diagnostic tests move from the
laboratory to the field during scale-up. Even
for diagnostics that demonstrate exceptional
specificity in controlled settings (and for TB,
where no existing test can prove absence of
disease, specificity is difficult to determine),
suboptimal performance is expected when
used by health workers with little laboratory
training or external quality control. In
particular, molecular TB diagnostics have
lower sensitivity and specificity when used
outside the laboratory [14], due in part to
higher rates of sample contamination [15].
Furthermore, TB prevalence is generally
lower in field settings than in controlled
studies, which appropriately enrich their
populations with TB cases to maximize
power. For example, Xpert MTB/RIF was
initially tested in a population with 55% TB
Summary Points
N Standard cost-effectiveness analyses may give misleading results when applied
blindly to the scale-up of TB diagnostics.
N Challenges in economic analysis of TB diagnostic tests include: underestimating
the cost of false-positive diagnoses, overlooking operational and clinical impact
of diagnostics, and utilizing unrealistic cost-effectiveness thresholds.
N Solutions include: establishing society’s valuation of false-positive tests,
evaluating the consequences of TB misdiagnosis in field settings, and setting
local cost-effectiveness thresholds for disease-specific interventions.
N Flexible and accessible analytic tools are needed for decision-makers to adapt
large-sample cost-effectiveness data to local conditions.
Figure 1. Schematic decision analysis. Decision tree for a hypothetical cost-effectiveness
analysis comparing sputum smear microscopy (blue) against Xpert MTB/RIF (red). Circles
represent chance nodes, where probabilities are applied to each branch as described in italics.
Triangles represent terminal nodes, where costs and effectiveness are calculated. Squares
demonstrate the points in the analysis at which the analytic challenges described in the text are
encountered.
doi:10.1371/journal.pmed.1001063.g001
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99.2% and identifying 25 new smear-
negative TB cases for each false-positive
[3]. However, if implemented with 95%
specificity in a field setting having 10% TB
prevalence, where 50% of TB is smear-
positive and 50% of smear-negative TB is
detected clinically, Xpert MTB/RIF would
identify 2.6 false-positives for every new
smear-negative TB case. Thus, standard
economic analyses of TB diagnostics relying
on controlled studies to estimate sensitivity,
specificity, and TB prevalence may simulta-
neously underestimate both the cost and
frequency of false-positive TB diagnoses.
Multiplying these figures to generate a cost-
effectiveness ratio may result in considerable
bias.
Challenge #2: Estimating
Operational and Clinical Impact
Disease diagnosis and management is a
complex and dynamic process, of which a
test’s diagnostic accuracy is only a small
component (Figure 2). Throughout this
process, patients’ clinical manifestations
progress, thresholds for empiric treatment
evolve [16], and different members of the
health care system interact. As a result, lab-
based estimates of diagnostic accuracy may
not correlate with operational or clinical
impact in the field. For example, in one
study of peripheral clinics in Uganda, only
21% of individuals with suspected TB were
referred for microscopy, and 71% of
patients with positive smears initiated TB
treatment [17]. A typical analysis assuming
that all individuals with suspected TB are
tested and all true-positives are treated
would greatly overestimate a diagnostic
test’s effectiveness under these conditions.
Other operational realities rarely incorpo-
rated into analyses of TB diagnostics
include empiric treatment (where diagnos-
tic test results do not affect outcome), time
delays in obtaining results, impact of test
results on physician behaviors, difficulty in
maintaining high-quality laboratory servic-
es, and disease progression with repeated
testing (where initial false-negative results
are subsequently corrected). Thus, the
number of positive test results estimated
from adding new diagnostics (e.g., Xpert
MTB/RIF) to existing algorithms does not
necessarily predict the number of positive
clinical outcomes achieved. Operational
data (e.g., [4]) mustbe incorporated as well.
Challenge #3: Setting Cost-
Effectiveness Thresholds
Public health resources in most coun-
tries are partitioned along disease-specific
lines. Thus, scale-up of diagnostics often
competes for resources against other
interventions targeting the same disease.
For TB, this might include additional
infrastructure for directly observed thera-
py, or external quality assessment of
microscopy. TB treatment is among the
most cost-effective health interventions
available. In Africa, for example, treating
smear-positive TB costs US$8 per DALY
averted [18]. Although there is no univer-
sal threshold for ‘‘cost-effectiveness,’’
many cost-effectiveness ratios are implicit-
ly benchmarked against the annual per-
capita GDP ($US$300 in all countries
except Zimbabwe [19]). Using this bench-
mark, a new TB diagnostic test costing
US$170 per DALY averted [10] might
appear economically favorable, but its
scale-up could divert resources from other,
more cost-effective interventions (such as
expanded access to high-quality microsco-
py). Diversion of resources to scale-up
rapid diagnostic tests is not simply a
theoretical concern. In India, for example,
providing Xpert MTB/RIF at current
prices to 15% of all TB suspects would
consume the entire annual budget of the
Revised National TB Control Program
(US$65 million in 2010) (D. Dowdy, K.
Steingart, M. Pai, unpublished data).
Improving Current Approaches
Scale-up of TB diagnostics will soon
occur, with or without economic analyses
to inform the process. Addressing the
challenges outlined above will lead to
better-informed policy recommendations
and scale-up decisions, and ultimately to
improved TB health outcomes worldwide.
Many organizations, including the WHO,
have adopted the Grading of Recommen-
dations, Assessment, Development, and
Evaluation (GRADE) approach to assess-
ing quality of evidence and determining
strength of recommendations for diagnos-
tic tests and strategies [20]. An Impact
Assessment Framework for TB diagnostics
has also been proposed [21] in which
scale-up analysis—including economic
evaluation—informs policy analysis. The
GRADE approach strongly considers pa-
tient-important outcomes, values and pref-
erences, and resource use. Using these
same principles to drive economic analyses
of TB diagnostics will enhance policy
relevance and provide more appropriate
guidance to scale-up recommended diag-
nostic tests.
To estimate the cost of false-positive
diagnoses, decision-makers should consid-
er local preferences for decreasing false-
positive versus false-negative test results.
Simple surveys of patients, physicians, and
members of society can be helpful. For
example, clinicians in Ecuador, Laos,
Nepal, and Rwanda were willing to treat
two false-positives to prevent one undiag-
nosed case of TB [22]. For scale-up in this
setting (from the physicians’ perspective),
an analysis should value the cost of false-
positives as one-half that of false-negatives.
When local preferences seem inappropri-
ate to policy-makers, educational efforts or
recommendations for empiric therapy
should be prioritized over scale-up of
novel diagnostics. Data should also be
collected on the morbidity and mortality
suffered by patients with other conditions
who are inappropriately diagnosed and
treated for TB.
To estimate the operational impact of
rapid diagnostics, decision-makers need
comparative data on patient- and provid-
er-important outcomes in clinical sites with
and without test access. Cluster-random-
ized trials (potentially with stepped-wedge
randomization [23]) could provide such
information. Study outcomes should in-
clude incidence and mortality (both dis-
ease-specific and all-cause), physician judg-
ment (to estimate rates of empiric
treatment), long-term follow-up (to charac-
terize repeated diagnostic attempts), and
quality-of-life surveys. Mathematical mod-
els could use these data to project the
medium-term impact and cost-effectiveness
of scaling-up TB diagnostics, ideally incor-
porating the ‘‘multiplier’’ effect of trans-
mission. Before scaling-up new diagnostics,
appropriate infrastructure must be devel-
oped to ensure that diagnostic results
translate into patient outcomes [8].
To set appropriate cost-effectiveness
thresholds, the activities that would be
supplanted by scaling-up rapid diagnostics
should be identified. Cost-effectiveness
analyses could then better define the
(willingness-to-pay) threshold at which
new diagnostics should be scaled-up.
Ultimately, decisions regarding scale-up
of rapid diagnostics will be made at the
national or sub-national level, and relevant
data will vary widely between locations
and constituencies (e.g., public versus
private sector). To be most effective, such
decisions must take into account not only
test accuracy and cost, but also the
socioeconomic factors that drive most TB
epidemics [24]. Model studies conducted
in representative populations can inform
broad guidelines, but local adaptation
should be emphasized. This process may
be facilitated by developing flexible and
accessible analytic tools that combine data
from larger studies with smaller evalua-
tions of local preferences, practices, and
PLoS Medicine | www.plosmedicine.org 3 July 2011 | Volume 8 | Issue 7 | e1001063economic conditions. At least one crude
but prototypical tool based on a published
analysis of hypothetical TB diagnostic tests
[10] is currently available online [25].
Conclusions
Standard cost-effectiveness analyses
may give misleading results when applied
blindly to the scale-up of TB diagnostics.
To be useful to both policy-makers and
decision-makers, such analyses should (1)
establish society’s valuation of false-posi-
Figure 2. Process of TB diagnosis. Boxes represent steps in the diagnostic process that must be completed for patients to experience positive
clinical outcomes. Accuracy of the diagnostic test (depicted in red) plays a necessary but small role.
doi:10.1371/journal.pmed.1001063.g002
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evaluate the consequences of false-nega-
tive and false-positive diagnoses when new
diagnostics are deployed in field settings,
and (3) set local cost-effectiveness thresh-
olds for disease-specific interventions.
Model studies and analytic tools allowing
flexible user-defined inputs can help local
decision-makers adapt broad policy guide-
lines to local conditions. Confronting these
challenges will help ensure that innova-
tions in TB diagnostic testing lead to
improved patient and population health
worldwide.
Author Contributions
Wrote the first draft: DWD. Contributed to the
writing of the manuscript: DWD AC KRS MP.
ICMJE criteria for authorship read and met:
DWD AC KRS MP. Agree with the manu-
script’s results and conclusions: DWD AC KRS
MP.
References
1. Pai M, Minion J, Steingart K, Ramsay A (2010)
New and improved tuberculosis diagnostics:
evidence, policy, practice, and impact. Curr Opin
Pulm Med 16: 271–284.
2. World Health Organization (2010) Framework for
implementing new tuberculosis diagnostics. Gene-
va: WHO, Available: http://www.who.int/tb/
laboratory/whopolicyframework_july10_revnov10.
pdf. Accessed 24 June 2011.
3. Boehme CC, Nabeta P, Hillemann D, Nicol MP,
Shenai S, et al. (2010) Rapid molecular detection of
tuberculosis and rifampin resistance. N Engl J Med
363: 1005–1015.
4. Boehme CC, Nicol MP, Nabeta P, Michael JS,
Gotuzzo E, et al. (2011) Feasibility, diagnostic
accuracy, and effectiveness of decentralized use of
the Xpert MTB/RIF test for diagnosis of tubercu-
losis and multidrug resistance: a multicentre
implementation study. Lancet 377: 1495–1505.
5. World Health Organization (2010) WHO endors-
es new rapid tuberculosis test. Available: http://
www.who.int/tb/features_archive/new_rapid_test/
en/. Accessed 13 March 2011.
6. Foundation for Innovative New Diagnostics (2010)
FIND Negotiated Priced for Xpert MTB/RIF and
Country List. Available: http://www.finddiagnostics.
org/programs/tb/find-negotiated-prices/xpert_mtb
_rif.html. Accessed 7 March 2011.
7. Russell LB, Gold MR, Siegel JE, Daniels N,
Weinstein MC (1996) The role of cost-effectiveness
analysis in health and medicine. Panel on cost-
effectiveness in health and medicine. JAMA 276:
1172–1177.
8. Dowdy DW, Lourenc ¸o MC, Cavalcante SC,
Saraceni V, King B, et al. (2008) Impact and cost-
effectiveness of culture for diagnosis of tuberculosis in
HIV-infected Brazilian adults. PLoS ONE 3: e4057.
9. Acuna-Villaorduna C, Vassall A, Henostroza G,
Seas C, Guerra H, et al. (2008) Cost-effectiveness
analysis of introduction of rapid, alternative
methods to identify multidrug-resistant tubercu-
losis in middle-income countries. Clin Infect Dis
47: 487–495.
10. Dowdy DW, O’Brien MA, Bishai D (2008) Cost-
effectiveness of novel diagnostic tools for the
diagnosis of tuberculosis. Int J Tuberc Lung Dis
12: 1021–1029.
11. Commission on Macroeconomics and Health
(2001) Macroeconomics and health: investing in
health for economic development. Geneva:
World Health Organization.
12. Scherer LC, Sperhacke RD, Ruffino-Netto A,
Rossetti ML, Vater C, et al. (2009) Cost-
effectiveness analysis of PCR for the rapid
diagnosis of pulmonary tuberculosis. BMC Infect
Dis 9: 216.
13. Basinga P, Moreira J, Bisoffi Z, Bisig B, Van den
Ende J (2007) Why are clinicians reluctant to treat
smear-negative tuberculosis? An inquiry about
treatment thresholds in Rwanda. Med Decis
Making 27: 53–60.
1 4 .D i n n e sJ ,D e e k sJ ,K u n s tH ,G i b s o nA ,
Cummins E, et al. (2007) A systematic review of
rapid diagnostic tests for the detection of
tuberculosis infection. Health Technol Assess
11: 1–196.
15. Ling DI, Flores LL, Riley LW, Pai M (2008)
Commercial nucleic-acid amplification tests for
diagnosis of pulmonary tuberculosis in respiratory
specimens: meta-analysis and meta-regression.
PLoS ONE 3: e1536.
16. Pauker SG, Kassirer JP (1980) The threshold
approachtoclinicaldecisionmaking.NEnglJMed
302: 1109–1117.
17. Davis JL, Katamba A, Vasquez J, Crawford E,
SSerwanga A, et al. (2011) Evaluating Tubercu-
losis Case Detection via Real-time Monitoring of
Tuberculosis Diagnostic Services. Am J Respir
Crit Care Med, In press.
18. Baltussen R, Floyd K, Dye C (2005) Cost
effectiveness analysis of strategies for tuberculosis
control in developing countries. BMJ 331: 1364.
19. Central Intelligence Agency (2010) CIA world
factbook. CIA: Washington (D.C.). Available:
https://www.cia.gov/library/publications/the-
world-factbook. Accessed 25 March 2011.
20. Schu ¨nemann HJ,Oxman AD,BrozekJ,Glasziou P,
Jaeschke R, etal. (2008) Grading quality of evidence
andstrengthof recommendations fordiagnostictests
and strategies. BMJ 336: 1106–1110.
21. Mann G, Squire SB, Bissell K, Eliseev P, Du
Toit E, et al. (2010) Beyond accuracy: creating a
comprehensive evidence base for TB diagnostic
tools. Int J Tuberc Lung Dis 14: 1518–1524.
22. Moreira J, Bisig B, Muwawenimana P, Basinga P,
Bisoffi Z, et al. (2009) Weighing harm in
therapeutic decisions of smear-negative pulmonary
tuberculosis. Med Decis Making 29: 380–390.
23. MoultonLH,GolubJE,DurovniB,CavalcanteSC,
Pacheco AG, et al. (2007) Statistical design of
THRio: a phased implementation clinic-random-
ized study of a tuberculosis preventive therapy
intervention. Clin Trials 4: 190–199.
24. Frieden TR (2009) Lessons from tuberculosis
control for public health. Int J Tuberc Lung Dis
13: 421–428.
25. Bishai D (2009) Cost-effectiveness of screening for
tuberculosis. Available: http://www.tbtools.org/.
Accessed 14 March 2011.
PLoS Medicine | www.plosmedicine.org 5 July 2011 | Volume 8 | Issue 7 | e1001063